CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$5.53 USD
+0.09 (1.58%)
Updated Oct 4, 2024 01:29 PM ET
After-Market: $5.60 +0.07 (1.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMCASI Pharmaceuticals Inc. (CASI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.00 | $6.00 | $6.00 | 10.29% |
Price Target
Only one analyst offered a short-term price target of $6.00 for CASI Pharmaceuticals Inc. This represents an increase of 10.29% from the last closing price of $5.44.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for CASI Pharmaceuticals Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | H.C. Wainwright & Co. | Sean Lee | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $6.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | NA |
CASI FAQs
CASI Pharmaceuticals Inc. (CASI) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for CASI Pharmaceuticals Inc. (CASI) is $6.00. The current on short-term price targets is based on 0 reports.
The forecasts for CASI Pharmaceuticals Inc. (CASI) range from a low of $6 to a high of $6. The average price target represents a increase of $8.50 from the last closing price of $5.53.
The current UPSIDE for CASI Pharmaceuticals Inc. (CASI) is 8.50%
Only one analyst offered a short-term price target of $6.00 for CASI Pharmaceuticals Inc. This represents an increase of 10.29% from the last closing price of $5.44.